FOV1101
Phase 2- Indications
- Chronic allergic conjunctivitis
Company intelligence / Profile preview
Fovea Pharmaceuticals
Paris, Ile-de-France, Franceorpha.net ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Fovea had three clinical compounds at the time of acquisition: FOV 1101 (Phase II for persistent allergic conjunctivitis), FOV 2302 (Phase I for retinal vein occlusion induced macular edema), and FOV 2304 (scheduled to enter Phase I for diabetic macular oedema)
- Therapeutic areas
- OphthalmologyEndocrinologyImmunology
- Modalities
- Small moleculeseye dropsintravitreal formulations
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
CombinatoRxDyax Corp
Beyond the preview
Go deeper on Fovea Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fovea Pharmaceuticals.